TORISEL var også forbundet med statistisk signifikante fordele frem for IFN- α i de sekundære endemål for PFS, TTF og klinisk nyttegrad.
TORISEL also was associated with statistically significant advantages over IFN-α in the secondary endpoints of PFS, TTF, and clinical benefit rate.